Loading…
Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer
OBJECTIVE To explore the possibility that allogeneic responses might, by chance, encompass cross‐reactive T cell clones specific for neo‐antigenic tumour determinants, and thereby activate antitumour immunity; such cross‐reactions are well documented for antiviral immunity, and genetic instability i...
Saved in:
Published in: | BJU international 2006-11, Vol.98 (5), p.989-995 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | OBJECTIVE
To explore the possibility that allogeneic responses might, by chance, encompass cross‐reactive T cell clones specific for neo‐antigenic tumour determinants, and thereby activate antitumour immunity; such cross‐reactions are well documented for antiviral immunity, and genetic instability in developing cancers generates many neo‐antigenic determinants as potential targets for immune responses, but the biology inevitably favours tumour progression.
PATIENTS AND METHODS
Fourteen patients with hormone‐refractory prostate cancer received full‐thickness skin allografts from different, unrelated donors (fellow patients) until each had received six grafts. Serum prostate‐specific antigen (PSA) level was used as a surrogate for tumour mass.
RESULTS
One patient had a remarkable decline in PSA level, with levels at 1 year lower than before grafting. A second patient had stable PSA levels for almost 2 years. A third patient had stable PSA levels for 10–12 months before they resumed an exponential rise. Of four patients with PSA levels of >10 ng/mL, three required surgery or radiotherapy for obstructive symptoms during or shortly after grafting.
CONCLUSION
Transplant rejection involves mechanistically atypical T cell recognition of allogeneic major histocompatibility complex antigens, with massive polyclonal T cell activation. This unique aspect of T cell biology might represent a novel approach for initiating cross‐reactive antitumour responses. |
---|---|
ISSN: | 1464-4096 1464-410X |
DOI: | 10.1111/j.1464-410X.2006.06421.x |